| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-44196 | |||
| BSA Free | NBP2-61428-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-21353-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26119-50ul | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | IC2729A | |||
| Biotin | BAF2729 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF2729 | |||
| Carrier Free | IC2729A | |||
| Carrier Free | AF2729-SP | |||
![Immunocytochemistry/Immunofluorescence: Nanog Antibody (CL5803) [NBP2-61428] - Staining of NTERA-2 cells using the Anti-NANOG monoclonal antibody, showing specific staining in the nucleoplasm in green. Microtubule and nuclear probes are visualized in red and blue, respectively (where available). Antibody staining is shown in green.](http://images.novusbio.com/fullsize/Nanog-Antibody-CL5803-Immunocytochemistry-Immunofluorescence-NBP2-61428-img0001.jpg "Immunocytochemistry/Immunofluorescence: Nanog Antibody (CL5803) [NBP2-61428] - Staining of NTERA-2 cells using the Anti-NANOG monoclonal antibody, showing specific staining in the nucleoplasm in green. Microtubule and nuclear probes are visualized in red and blue, respectively (where available). Antibody staining is shown in green.")
![Immunohistochemistry-Paraffin: Nanog Antibody (CL5803) [NBP2-61428] - Staining of human testis shows absence of positivity as expected (negative control).](http://images.novusbio.com/fullsize/Nanog-Antibody-CL5803-Immunohistochemistry-Paraffin-NBP2-61428-img0004.jpg)
![Immunohistochemistry-Paraffin: Nanog Antibody (CL5803) [NBP2-61428] - Staining of human testis cancer shows strong nuclear immunoreactivity in tumor cells.](http://images.novusbio.com/fullsize/Nanog-Antibody-CL5803-Immunohistochemistry-Paraffin-NBP2-61428-img0002.jpg)
![Immunohistochemistry-Paraffin: Nanog Antibody (CL5803) [NBP2-61428] - Staining of human bladder cancer shows absence of positivity in tumor cells as expected (negative control).](http://images.novusbio.com/fullsize/Nanog-Antibody-CL5803-Immunohistochemistry-Paraffin-NBP2-61428-img0003.jpg)
![Western Blot: Nanog Overexpression Lysate (Adult Normal) [NBL1-13465] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for Nanog.](http://images.novusbio.com/fullsize/Nanog-Overexpression-Lysate-Adult-Normal-Western-Blot-NBL1-13465-img0002.jpg "Western Blot: Nanog Overexpression Lysate (Adult Normal) [NBL1-13465] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for Nanog.")
![SDS-Page: Recombinant Human Nanog Protein [NBP1-72387] - 15% SDS-PAGE (3ug)](http://images.novusbio.com/fullsize/Recombinant-Human-Nanog-Protein-SDS-Page-NBP1-72387-img0001.jpg "SDS-Page: Recombinant Human Nanog Protein [NBP1-72387] - 15% SDS-PAGE (3ug)")
![Flow Cytometry: Nanog Antibody (2G6) [NBP3-26119] - Overlay Peak curve showing Hela cells stained with Nanog Antibody (2G6) (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% Triton X-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4C. Control antibody (green line) was rabbit IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed.](http://images.novusbio.com/fullsize/nbp3-26119_rabbit-nanog-mab-2g6-282202414312711.jpg "Flow Cytometry: Nanog Antibody (2G6) [NBP3-26119] - Overlay Peak curve showing Hela cells stained with Nanog Antibody (2G6) (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% Triton X-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4C. Control antibody (green line) was rabbit IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed.")
![Western Blot: Nanog Antibody [NB100-588] - ZNF217 and ALKBH5 regulate NANOG and KLF4 expression via modulation of m6A levels. MCF-7 subclones were exposed to 20% or 1% O2 for 48 h and immunoblot assays were performed. H. MCF-7 subclones were exposed to 20% or 1% O2 for 48 h. The percentage of m6A+ KLF4 mRNA was determined. *P < 0.05, **P < 0.01 vs. NTC at 20% O2; ##P < 0.01 vs. NTC at 1% O2 by two-way ANOVA. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/fulltext/11743), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Nanog-Antibody-Western-Blot-NB100-588-img0010.jpg "<b>Biological Strategies Validation. </b>Western Blot: Nanog Antibody [NB100-588] - ZNF217 and ALKBH5 regulate NANOG and KLF4 expression via modulation of m6A levels. MCF-7 subclones were exposed to 20% or 1% O2 for 48 h and immunoblot assays were performed. H. MCF-7 subclones were exposed to 20% or 1% O2 for 48 h. The percentage of m6A+ KLF4 mRNA was determined. *P < 0.05, **P < 0.01 vs. NTC at 20% O2; ##P < 0.01 vs. NTC at 1% O2 by two-way ANOVA. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/fulltext/11743), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Flow Cytometry: Nanog Antibody [NB100-588] - FACS analysis of Nanog expression in primary mouse hepatic stellate cell cultured for 7 days. Image from verified customer review.](http://images.novusbio.com/fullsize/Nanog-Antibody-Flow-Cytometry-NB100-588-img0005.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: Nanog Antibody [NB100-588] - Detection of Mouse Nanog by Western Blot and Immunoprecipitation.](http://images.novusbio.com/fullsize/Nanog-Antibody-Western-Blot-NB100-588-img0004.jpg)
![Western Blot: Nanog Antibody [NB100-588] - The expression of pluripotency factor Nanog in human head and neck cancer cell lines cell lines FaDu and HN5. WB from a verified customer review.](http://images.novusbio.com/fullsize/Nanog-Antibody-Western-Blot-NB100-588-img0007.jpg)
![Western Blot: Nanog Antibody [NB100-588] - Detection of mouse Nanog by western blot. Samples: Whole cell lysate (50 ug) from F9 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Nanog antibody NB100-588 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/Nanog-Antibody-Western-Blot-NB100-588-img0008.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: Nanog Antibody [NB100-588] - HIFs are required for hypoxia-induced expression of pluripotency factors. ZR75.1 cells were treated with vehicle or digoxin (200 nM), exposed to 20% or 1% O2 for 48 h, and HIF-1alpha, NANOG and SOX2 immunoblot assays were performed. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/fulltext/11743), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Nanog-Antibody-Western-Blot-NB100-588-img0009.jpg)
![Flow Cytometry: Nanog Antibody [NB100-588] - staining of NTERA-2 cells using NB100-588 at a 1:50 dilution detected using Dylight-488 conjugated goat anti-rabbit secondary antibody.](http://images.novusbio.com/fullsize/Nanog-Antibody-Flow-Cytometry-NB100-588-img0003.jpg)
![Western Blot: Nanog Antibody [NB100-588] - HIFs are required for hypoxia-induced expression of pluripotency factorsA-C. Breast cancer cell lines were exposed to 20% or 1% O2 for 24 h & NANOG (A), KLF4 (B), & SOX2 (C) mRNA levels were determined by RT-qPCR, relative to 18S rRNA, & normalized to the mean value for MDA-MB-231 cells (MDA231) at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. same cell line at 20% O2 by Student's t test. D & E. HCC-1954 (D) & MCF-7 (E) subclones, which were stably transfected with an expression vector encoding a non-targeting control (NTC) shRNA, or vector encoding shRNA targeting HIF-1 alpha (sh1 alpha ) or HIF-2 alpha (sh2 alpha ), or vectors encoding shRNAs targeting both HIF-1 alpha & HIF-2 alpha (DKD), were exposed to 20% or 1% O2 for 24 h & RT-qPCR was performed to determine NANOG (D) or KLF4 (E) mRNA levels relative to 18S rRNA. The results were normalized to NTC at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC at 20% O2; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. NTC at 1% O2 by ANOVA. F. ZR75.1 cells treated with vehicle or digoxin (200 nM) were exposed to 20% or 1% O2 for 24 h & SOX2 mRNA was measured (mean ± SEM; n = 3). *P < 0.05, **P < 0.01 vs. NTC at 20% O2; ###P < 0.001 vs. NTC at 1% O2 by ANOVA. G & H. NTC & DKD subclones of HCC-1954 (G) & MCF-7 (H) were exposed to 20% or 1% O2 for 48 h, whole cell lysates were prepared, & immunoblot assays were performed to analyze HIF-1 alpha , HIF-2 alpha , NANOG & KLF4 protein expression. Actin was also analyzed as a loading control. I. ZR75.1 cells were treated with vehicle or digoxin (200 nM), exposed to 20% or 1% O2 for 48 h, & HIF-1 alpha , NANOG & SOX2 immunoblot assays were performed. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11743), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-588_rabbit-polyclonal-nanog-antibody-310202415535155.jpg)
